Free tool
Large cap stocks
We cover 236 companies in the large cap size band. The median market value in the group is $32.02B. Across the group, the median move over the past trading day is +0.02%. 69% of the 229 with a 200-day average trade above it. Price change over the past year runs from −24.6% to +88.0% across the middle 80 percent of the group, with a median of +13.9%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
Table
236 of 2,795 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | $184.47B | Large cap | +32.85% |
| GILD34.SA | Gilead Sciences, Inc. | $184.17B | Large cap | −78.95% |
| GIS.DE | Gilead Sciences, Inc. | $183.56B | Large cap | +29.53% |
| PFE.DE | Pfizer Inc. | $162.65B | Large cap | +18.09% |
| PFIZ34.SA | Pfizer Inc. | $161.64B | Large cap | +11.31% |
| PFE | Pfizer Inc. | $159.42B | Large cap | +19.52% |
| DHR | Danaher Corporation | $151.82B | Large cap | +4.52% |
| DHER34.SA | Danaher Corporation | $151.72B | Large cap | −0.75% |
| DAP.DE | Danaher Corporation | $151.41B | Large cap | +5.45% |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $140.77B | Large cap | +40.14% |
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | $140.14B | Large cap | −83.17% |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.04B | Large cap | +42.14% |
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% |
| BMYB34.SA | Bristol-Myers Squibb Company | $138.65B | Large cap | +40.74% |
| BRM.DE | Bristol-Myers Squibb Company | $138.39B | Large cap | +46.24% |
| IUI1.DE | Intuitive Surgical, Inc. | $133.35B | Large cap | −20.90% |
| ISRG | Intuitive Surgical, Inc. | $133.22B | Large cap | −20.62% |
| I1SR34.SA | Intuitive Surgical, Inc. | $133.21B | Large cap | −24.38% |
| SYK | Stryker Corporation | $126.81B | Large cap | −14.79% |
| S1YK34.SA | Stryker Corporation | $126.62B | Large cap | −17.50% |
| SYK.DE | STRYKER CORP. R | $126.48B | Large cap | +34.76% |
| MDTC34.SA | Medtronic plc | $117.91B | Large cap | −76.08% |
| 2M6.DE | Medtronic plc | $117.39B | Large cap | +3.67% |
| MDT | Medtronic plc | $116.66B | Large cap | +1.33% |
| SNY | Sanofi | $110.27B | Large cap | −3.11% |
| SAN.PA | Sanofi | $110.15B | Large cap | −4.49% |
| SNW.DE | Sanofi | $109.49B | Large cap | −4.28% |
| MCK | McKesson Corporation | $105.52B | Large cap | +33.71% |
| GS71.DE | GSK plc | $104.54B | Large cap | +31.93% |
| G1SK34.SA | GSK plc | $104.53B | Large cap | +28.14% |
| GSK | GSK plc | $104.29B | Large cap | +34.79% |
| GSK.L | GSK plc | $104.16B | Large cap | +28.03% |
| M1CK34.SA | McKesson Corporation | $101.65B | Large cap | −92.48% |
| HCA | HCA Healthcare, Inc. | $95.12B | Large cap | +6.96% |
| H1CA34.SA | HCA Healthcare, Inc. | $92.89B | Large cap | +3.95% |
| A58.DE | Elevance Health, Inc. | $86.73B | Large cap | −18.92% |
| E1LV34.SA | Elevance Health, Inc. | $86.53B | Large cap | +21.66% |
| ELV | Elevance Health, Inc. | $86.50B | Large cap | +29.17% |
| RGO.DE | Regeneron Pharmaceuticals, Inc. | $86.30B | Large cap | −7.35% |
| ESL.DE | EssilorLuxottica Société anonyme | $85.86B | Large cap | −38.59% |
| REGN | Regeneron Pharmaceuticals, Inc. | $85.82B | Large cap | +46.21% |
| EL.PA | EssilorLuxottica Société anonyme | $85.41B | Large cap | −37.89% |
| REGN34.SA | Regeneron Pharmaceuticals, Inc. | $85.24B | Large cap | +37.96% |
| CI | The Cigna Group | $73.81B | Large cap | −5.62% |
| C1IC34.SA | The Cigna Group | $73.40B | Large cap | −85.51% |
| CGN.DE | The Cigna Group | $73.25B | Large cap | −8.36% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $73.00B | Large cap | +12.47% |
| B1SX34.SA | Boston Scientific Corporation | $72.28B | Large cap | −88.79% |
| BSX | Boston Scientific Corporation | $72.26B | Large cap | −52.56% |
| BSX.DE | Boston Scientific Corporation | $71.57B | Large cap | −54.21% |
| MRK.DE | Merck KGaA | $70.75B | Large cap | +30.60% |
| ARGX | argenx SE | $63.78B | Large cap | +50.52% |
| M1RN34.SA | Moderna, Inc. | $63.51B | Large cap | +494.34% |
| 0QF.DE | Moderna, Inc. | $63.46B | Large cap | +461.14% |
| MRNA | Moderna, Inc. | $63.41B | Large cap | +526.55% |
| A1RG34.SA | argenx SE | $63.17B | Large cap | +44.49% |
| COR | Cencora, Inc. | $62.60B | Large cap | +14.44% |
| CSL.AX | CSL Limited | $59.98B | Large cap | −17.14% |
| 4502.T | Takeda Pharmaceutical Company Limited | $58.99B | Large cap | +39.50% |
| TAK | Takeda Pharmaceutical Company Limited | $58.60B | Large cap | +21.77% |
| TAKP34.SA | Takeda Pharmaceutical Company Limited | $57.23B | Large cap | +16.07% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.51B | Large cap | +71.10% |
| CAH | Cardinal Health, Inc. | $55.33B | Large cap | +64.25% |
| C1AH34.SA | Cardinal Health, Inc. | $55.24B | Large cap | +50.94% |
| BAY.WA | Bayer Aktiengesellschaft | $55.03B | Large cap | +71.25% |
| 207940.KS | Samsung Biologics Co.,Ltd. | $53.31B | Large cap | +2.60% |
| C1CO34.SA | Cencora, Inc. | $52.36B | Large cap | −12.17% |
| EW | Edwards Lifesciences Corporation | $52.32B | Large cap | +12.38% |
| BOX.DE | Becton, Dickinson and Company | $52.05B | Large cap | +2.94% |
| EWL.DE | Edwards Lifesciences Corporation | $51.93B | Large cap | +10.23% |
| SHL.DE | Siemens Healthineers AG | $51.88B | Large cap | −12.35% |
| B1DX34.SA | Becton, Dickinson and Company | $51.78B | Large cap | −113.87% |
| BDX | Becton, Dickinson and Company | $51.69B | Large cap | +26.17% |
| 7741.T | HOYA Corporation | $51.57B | Large cap | +29.26% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.24% |
| E1WL34.SA | Edwards Lifesciences Corporation | $47.29B | Large cap | −4.72% |
| MDLN | Medline Inc. | $46.69B | Large cap | −13.07% |
| HUM | Humana Inc. | $46.42B | Large cap | +32.71% |
| H1UM34.SA | Humana Inc. | $45.80B | Large cap | +24.30% |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% |
| HLN | Haleon plc | $44.77B | Large cap | +6.56% |
| H6D0.DE | Haleon plc | $44.53B | Large cap | +4.86% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.40B | Large cap | +110.26% |
| HLN.L | Haleon plc | $44.36B | Large cap | +2.08% |
| I1DX34.SA | IDEXX Laboratories, Inc. | $44.35B | Large cap | −16.38% |
| IDXX | IDEXX Laboratories, Inc. | $43.39B | Large cap | −14.24% |
| A | Agilent Technologies, Inc. | $43.33B | Large cap | +30.69% |
| T1EV34.SA | Teva Pharmaceutical Industries Limited | $43.18B | Large cap | +94.70% |
| IX1.DE | IDEXX Laboratories, Inc. | $43.12B | Large cap | +17.97% |
| IQV | IQVIA Holdings Inc. | $42.70B | Large cap | +37.97% |
| QTS.DE | IQVIA Holdings Inc. | $42.69B | Large cap | −3.91% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +21.95% |
| V2EE34.SA | Veeva Systems Inc. | $41.01B | Large cap | −16.69% |
| WAT | Waters Corporation | $40.69B | Large cap | +38.63% |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.62B | Large cap | +58.81% |
| VEEV | Veeva Systems Inc. | $40.09B | Large cap | −13.47% |
| VEE.DE | Veeva System Inc. R | $40.06B | Large cap | +13.96% |
| A1GI34.SA | Agilent Technologies, Inc. | $39.64B | Large cap | −77.11% |
| WATC34.SA | Waters Corporation | $36.36B | Large cap | +24.76% |
| ALC | Alcon Inc. | $35.47B | Large cap | −8.71% |
| RPRX | Royalty Pharma plc | $35.44B | Large cap | +75.10% |
| 2U3.DE | Alcon Inc. | $35.35B | Large cap | −10.05% |
| DC4.DE | DexCom, Inc. | $34.19B | Large cap | +21.55% |
| RMD | ResMed Inc. | $34.13B | Large cap | −16.58% |
| I1LM34.SA | Illumina, Inc. | $34.11B | Large cap | +113.13% |
| RMD.AX | ResMed Inc. | $34.05B | Large cap | −24.73% |
| ILU.DE | Illumina, Inc. | $34.04B | Large cap | +119.28% |
| ILMN | Illumina, Inc. | $33.97B | Large cap | +125.76% |
| D1EX34.SA | DexCom, Inc. | $33.83B | Large cap | +11.74% |
| DXCM | DexCom, Inc. | $33.65B | Large cap | +17.38% |
| GEHC | GE HealthCare Technologies Inc. | $33.62B | Large cap | −0.78% |
| 4568.T | Daiichi Sankyo Company, Limited | $33.36B | Large cap | −15.95% |
| IDP.DE | Biogen Inc. | $32.80B | Large cap | +57.35% |
| C1NC34.SA | Centene Corporation | $32.65B | Large cap | +116.81% |
| BIIB | Biogen Inc. | $32.62B | Large cap | +61.90% |
| BIIB34.SA | Biogen Inc. | $32.56B | Large cap | +47.86% |
| ALNY | Alnylam Pharmaceuticals, Inc. | $32.12B | Large cap | −45.88% |
| CNC | Centene Corporation | $32.11B | Large cap | +123.52% |
| ZTS | Zoetis Inc. | $31.94B | Large cap | −49.59% |
| 068270.KS | Celltrion, Inc. | $31.91B | Large cap | +13.47% |
| Z1TS34.SA | Zoetis Inc. | $31.90B | Large cap | −52.14% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | $31.87B | Large cap | −11.75% |
| A1LN34.SA | Alnylam Pharmaceuticals, Inc. | $31.78B | Large cap | −49.89% |
| ZOE.DE | Zoetis Inc. | $31.72B | Large cap | −50.09% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.15B | Large cap | +1.55% |
| 22UA.DE | BioNTech SE | $29.53B | Large cap | +8.53% |
| B1NT34.SA | BioNTech SE | $28.89B | Large cap | +3.26% |
| BNTX | BioNTech SE | $28.65B | Large cap | +8.55% |
| MTD | Mettler-Toledo International Inc. | $28.10B | Large cap | +8.72% |
| MTO.DE | Mettler-Toledo International Inc. | $27.84B | Large cap | +13.15% |
| 4503.T | Astellas Pharma Inc. | $27.40B | Large cap | +56.44% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +23.25% |
| R1MD34.SA | ResMed Inc. | $27.30B | Large cap | −38.24% |
| INSM | Insmed Incorporated | $27.07B | Large cap | −3.45% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.70% |
| PHG | Koninklijke Philips N.V. | $26.81B | Large cap | +3.60% |
| PHI1.DE | Koninklijke Philips N.V. | $26.73B | Large cap | +2.84% |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% |
| ROIV | Roivant Sciences Ltd. | $26.26B | Large cap | +213.32% |
| I1NC34.SA | Incyte Corporation | $25.83B | Large cap | +41.91% |
| WST | West Pharmaceutical Services, Inc. | $24.52B | Large cap | +41.31% |
| 4543.T | Terumo Corporation | $24.11B | Large cap | −1.19% |
| SIG.AX | Sigma Healthcare Limited | $23.62B | Large cap | −5.33% |
| STE | STERIS plc | $23.05B | Large cap | −4.35% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $22.07B | Large cap | +10.02% |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $22.06B | Large cap | +10.46% |
| GH | Guardant Health, Inc. | $21.90B | Large cap | +166.52% |
| THC | Tenet Healthcare Corporation | $21.89B | Large cap | +54.57% |
| GMAB | Genmab A/S | $21.42B | Large cap | +41.34% |
| GE9.DE | GENMAB AS N | $21.11B | Large cap | −14.41% |
| GMAB.CO | Genmab A/S | $21.08B | Large cap | +33.08% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.88B | Large cap | +26.10% |
| S1TE34.SA | STERIS plc | $19.75B | Large cap | −18.78% |
| VTRS | Viatris Inc. | $19.20B | Large cap | +62.88% |
| VIA.DE | Viatris Inc. | $19.14B | Large cap | +62.09% |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.12B | Large cap | −5.86% |
| QS51.DE | Straumann Holding AG | $18.25B | Large cap | +0.41% |
| Z1BH34.SA | Zimmer Biomet Holdings, Inc. | $18.07B | Large cap | −5.04% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $17.32B | Large cap | +54.48% |
| MEDP | Medpace Holdings, Inc. | $17.31B | Large cap | +31.55% |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | +108.87% |
| ASND | Ascendis Pharma A/S | $16.59B | Large cap | +32.89% |
| COLO-B.CO | Coloplast A/S | $16.31B | Large cap | −20.81% |
| CBHD.DE | Coloplast A/S | $16.19B | Large cap | +7.28% |
| IPN.PA | Ipsen S.A. | $16.01B | Large cap | +39.21% |
| BBIO | BridgeBio Pharma, Inc. | $15.85B | Large cap | +70.01% |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $15.80B | Large cap | +13.60% |
| SRT.DE | Sartorius Aktiengesellschaft | $15.72B | Large cap | +22.06% |
| N1BI34.SA | Neurocrine Biosciences, Inc. | $15.69B | Large cap | +7.58% |
| 4507.T | Shionogi & Co., Ltd. | $15.68B | Large cap | +17.95% |
| SOLV | Solventum Corporation | $15.59B | Large cap | +25.92% |
| NBIX | Neurocrine Biosciences, Inc. | $15.59B | Large cap | +14.46% |
| RDOR3.SA | Rede D'Or São Luiz S.A. | $15.25B | Large cap | +5.51% |
| C1OO34.SA | The Cooper Companies, Inc. | $15.12B | Large cap | −0.30% |
| ERF.PA | Eurofins Scientific SE | $14.91B | Large cap | +13.76% |
| ESF0.DE | Eurofins Scientific SE | $14.63B | Large cap | +11.02% |
| 7733.T | Olympus Corporation | $14.46B | Large cap | +26.42% |
| COO | The Cooper Companies, Inc. | $14.25B | Large cap | −0.60% |
| CRL | Charles River Laboratories International, Inc. | $14.21B | Large cap | +81.37% |
| PME.AX | Pro Medicus Limited | $14.09B | Large cap | −38.33% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +35.78% |
| B1AX34.SA | Baxter International Inc. | $13.60B | Large cap | +2.30% |
| BAX | Baxter International Inc. | $13.59B | Large cap | +7.91% |
| ICLR | ICON Public Limited Company | $13.38B | Large cap | −1.65% |
| CORT | Corcept Therapeutics Incorporated | $13.36B | Large cap | +79.56% |
| ORNBV.HE | Orion Oyj | $13.29B | Large cap | +16.59% |
| ORNAV.HE | Orion Oyj | $13.24B | Large cap | +17.12% |
| S1NN34.SA | Smith & Nephew plc | $12.87B | Large cap | −20.44% |
| BMRN | BioMarin Pharmaceutical Inc. | $12.80B | Large cap | +13.03% |
| PEN | Penumbra, Inc. | $12.75B | Large cap | +22.79% |
| FME.DE | Fresenius Medical Care AG | $12.66B | Large cap | −3.50% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.60B | Large cap | +2.09% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +6.36% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.52B | Large cap | +329.16% |
| FMS | Fresenius Medical Care AG | $12.51B | Large cap | −3.29% |
| R1VT34.SA | Revvity, Inc. | $12.50B | Large cap | +22.81% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +51.39% |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | −9.45% |
| SNN | Smith & Nephew plc | $12.23B | Large cap | −19.49% |
| ELAN | Elanco Animal Health Incorporated | $12.20B | Large cap | +41.03% |
| SN.L | Smith & Nephew plc | $12.20B | Large cap | −21.69% |
| EHC | Encompass Health Corporation | $11.85B | Large cap | −1.16% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.83B | Large cap | +24.24% |
| A1LG34.SA | Align Technology, Inc. | $11.51B | Large cap | +7.83% |
| DVA | DaVita Inc. | $11.41B | Large cap | +29.47% |
| ALGN | Align Technology, Inc. | $11.34B | Large cap | +10.11% |
| BTSG | BrightSpring Health Services, Inc. | $11.32B | Large cap | +137.67% |
| AFW.DE | Align Technology, Inc. | $11.31B | Large cap | −54.37% |
| TECH | Bio-Techne Corporation | $11.27B | Large cap | +28.12% |
| T1CH34.SA | Bio-Techne Corporation | $11.23B | Large cap | +23.42% |
| GMED | Globus Medical, Inc. | $11.14B | Large cap | +35.16% |
| DVAI34.SA | DaVita Inc. | $11.11B | Large cap | +15.68% |
| I1QV34.SA | IQVIA Holdings Inc. | $10.82B | Large cap | −67.19% |
| CYTK | Cytokinetics, Incorporated | $10.77B | Large cap | +109.29% |
| AXSM | Axsome Therapeutics, Inc. | $10.76B | Large cap | +76.67% |
| GKOS | Glaukos Corporation | $10.70B | Large cap | +98.13% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% |
| IONS | Ionis Pharmaceuticals, Inc. | $10.56B | Large cap | +52.01% |
| KRYS | Krystal Biotech, Inc. | $10.54B | Large cap | +142.69% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +202.82% |
| BIO | Bio-Rad Laboratories, Inc. | $10.45B | Large cap | +31.26% |
| ENSG | The Ensign Group, Inc. | $10.43B | Large cap | +5.44% |
| ABVX.PA | ABIVAX Société Anonyme | $10.42B | Large cap | +42.59% |
| MOH | Molina Healthcare, Inc. | $10.42B | Large cap | +13.96% |
| BIM.PA | bioMérieux S.A. | $10.40B | Large cap | −37.52% |
| UHS | Universal Health Services, Inc. | $10.40B | Large cap | −4.14% |
| ABVX | ABIVAX Société Anonyme | $10.29B | Large cap | +52.25% |
| RDY | Dr. Reddy's Laboratories Limited | $10.28B | Large cap | −14.66% |
| PRAX | Praxis Precision Medicines, Inc. | $10.28B | Large cap | +684.02% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +49.84% |
| HSIC | Henry Schein, Inc. | $10.21B | Large cap | +30.93% |
| U1HS34.SA | Universal Health Services, Inc. | $10.21B | Large cap | −10.02% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +265.05% |
| RHCPA.AX | Ramsay Health Care Limited | $10.16B | Large cap | +0.44% |
| PTGX | Protagonist Therapeutics, Inc. | $10.01B | Large cap | +164.75% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.